COVID-19 and thrombosis: searching for evidence

Thilagar, Bright; Beidoun, Mohammad; Rhoades, Ruben; Kaatz, Scott

doi:10.1182/hematology.2021000298

Cited by 16 publications

(13 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It is well known now that contracting the novel coronavirus disease 2019 (COVID‐19) represents a significant hypercoagulable risk factor for VTE development, particularly in hospitalized patients with moderate and severe forms of COVID‐19 29 . The development of acute PE/VTE associated with or complicated by COVID‐19 represents a unique and challenging clinical scenario.…”

Section: Role Of Perts During the Covid‐19 Pandemicmentioning

confidence: 99%

Pulmonary embolism response teams: Changing the paradigm in the care for acute pulmonary embolism

Porres‐Aguilar

Rosovsky

Rivera‐Lebron

et al. 2022

Journal of Thrombosis and Haemostasis

Self Cite

View full text Add to dashboard Cite

Pulmonary embolism response teams (PERTs) have emerged as a multidisciplinary, multispecialty team of experts in the care of highly complex symptomatic acute pulmonary embolism (PE), with a centralized unique activation process, providing rapid multimodality assessment and risk stratification, formulating the best individualized diagnostic and therapeutic approach, streamlining the care in challenging clinical case scenarios (e.g., intermediate–high risk and high‐risk PE), and facilitating the implementation of the recommended therapeutic strategies on time. PERTs are currently changing how complex acute PE cases are approached. The structure, organization, and function of a given PERT may vary from hospital to hospital, depending on local expertise, specific resources, and infrastructure for a given academic hospital center. Current emerging data demonstrate the value of PERTs in improving time to PE diagnosis; shorter time to initiation of anticoagulation reducing hospital length of stay; increasing use of advanced therapies without an increase in bleeding; and in some reports, decreasing mortality. Importantly, PERTs are positively impacting outcomes by changing the paradigm of care for acute PE through global adoption by the health‐care community.

show abstract

Section: Role Of Perts During the Covid‐19 Pandemicmentioning

confidence: 99%

Pulmonary embolism response teams: Changing the paradigm in the care for acute pulmonary embolism

Porres‐Aguilar

Rosovsky

Rivera‐Lebron

et al. 2022

Journal of Thrombosis and Haemostasis

Self Cite

View full text Add to dashboard Cite

show abstract

“…Platelet hyperreactivity, which could result from direct viral invasion or indirect activation by cytokine release, and activation of the complement system may cause further cytokine release, stimulating the coagulation cascade and suppressing fibrinolysis. Additionally, patients with severe COVID-19 may have limited mobility, which promotes vascular stasis, platelet and erythrocyte aggregation, and thrombosis ( 9 ).…”

Section: Pathophysiology Of Sars-cov-2 Infectionmentioning

confidence: 99%

“…Thromboembolism may involve numerous organ systems. In addition to small vessel thrombosis, which is one of the hallmarks in autopsies of COVID-19 patients with respiratory and multisystem organ failure, large vessel venous thromboembolism is also common ( 9 ). Deep venous thrombosis (DVT) occurs in about 20%–25% of hospitalized patients and may result in pulmonary embolism ( 37 ).…”

Section: Covid-19 In Msk Systemmentioning

confidence: 99%

Musculoskeletal Manifestations of COVID-19: Currently Described Clinical Symptoms and Multimodality Imaging Findings

Omar¹,

Weaver²,

Samet³

et al. 2022

RadioGraphics

View full text Add to dashboard Cite

COVID-19, the clinical syndrome produced by infection with SARS-CoV-2, can result in multisystem organ dysfunction, including respiratory failure and hypercoagulability, which can lead to critical illness and death. Musculoskeletal (MSK) manifestations of COVID-19 are common but have been relatively underreported, possibly because of the severity of manifestations in other organ systems. Additionally, patients who have undergone sedation and who are critically ill are often unable to alert clinicians of their MSK symptoms. Furthermore, some therapeutic measures such as medications and vaccinations can worsen existing MSK symptoms or cause additional symptoms. Symptoms may persist or occur months after the initial infection, known as post-COVID condition or long COVID. As the global experience with COVID-19 and the vaccination effort increases, certain patterns of MSK disease involving the bones, muscles, peripheral nerves, blood vessels, and joints have emerged, many of which are likely related to a hyperinflammatory host response, prothrombotic state, or therapeutic efforts rather than direct viral toxicity. Imaging findings for various COVID-19–related MSK pathologic conditions across a variety of modalities are being recognized, which can be helpful for diagnosis, treatment guidance, and follow-up. The online slide presentation from the RSNA Annual Meeting is available for this article. © RSNA, 2022

show abstract

“…It has been suggested that the polyanionic constituents of the adenovirus vector-based vaccines trigger antibody production against PF4 (platelet factor 4) which, in turn, induce platelet activation. As a result, thrombocytopenia and thrombosis occur [63].…”

Section: Covid-19 Vaccine-induced Immune Thrombocytopenic Purpuramentioning

confidence: 99%

COVID-19-induced immune thrombocytopenic purpura; Immunopathogenesis and clinical implications

et al. 2022

View full text Add to dashboard Cite

Following the outbreak of the COVID-19 pandemic, millions of people around the world have been affected with SARS-CoV-2 infection. In addition to the typical symptoms, thrombotic events, lymphopenia, and thrombocytopenia have been reported in COVID-19 patients. Immune thrombocytopenic purpura (ITP) is one of the thrombotic events that occur in some COV-ID-19 patients. Hyperinflammation, cytokine storms, and immune dysregulation in some patients are the cause to the main COVID-19 complications such as ALI (acute lung injury), acute respiratory distress syndrome (ARDS), and multiple organ failure. Disruption in the differentiation of T-cells, enhanced differentiation of Th17 and Th1, cell death (pyroptosis), SUMMARYhyper-inflammation and dysfunction of inflammatory neutrophils and macrophages, and hyperactivity of NLRP3-inflammasome are among the important factors that may be the cause to COVID-19-induced ITP. This study aimed to give an overview of the findings on the immunopathogenesis of ITP and COVID-19-induced ITP. Further studies are required to better understand the exact immunopathogenesis and effective treatments for ITP, especially in inflammatory disorders.

show abstract

COVID-19 and thrombosis: searching for evidence

Cited by 16 publications

References 38 publications

Pulmonary embolism response teams: Changing the paradigm in the care for acute pulmonary embolism

Pulmonary embolism response teams: Changing the paradigm in the care for acute pulmonary embolism

Musculoskeletal Manifestations of COVID-19: Currently Described Clinical Symptoms and Multimodality Imaging Findings

COVID-19-induced immune thrombocytopenic purpura; Immunopathogenesis and clinical implications

Contact Info

Product

Resources

About